The class of drugs are Bi-specific T-cell engagers from what I understand. I have a relative going through treatment and the possibility of these treatments was

The class of drugs are Bi-specific T-cell engagers from what I understand. I have a relative going through treatment and the possibility of these treatments was raised so I have been reading some but I'm not claiming to be an expert. The risk of side effects like the Cytokine storm seems to be similar to CAR-T, but this type of treatment doesn't require the blood harvesting, cell modification, and return for reinfusion. It seems like a better (more generic) way of accomplishing something similar. In the case of the family member in question it sounds like one of these therapies are an option after CAR-T treatment currently. But it might be a preferable option in the future. I'm not sure if that is related to novelty and lack of data or something else.